Peroxisome proliferator-activated receptor {gamma} (PPARg), the nuclear receptor that binds the insulin-sensitizing thiazolidinediones (TZDs), is prominently upregulated in intimal vascular smooth muscle cells (VSMC) after mechanical injury to the vessel wall. Several TZD PPARg ligands have been shown to inhibit neointima formation in both normal and insulinresistant vasculature. The suppression of intimal hyperplasia by TZD PPARg ligands probably results from their activity to inhibit VSMC growth and promote apoptosis. TZDs prevent VSMC proliferation by blocking the activity of regulatory proteins, such as phosphorylation of the retinoblastoma protein (Rb). Rb functions as a G 1 gatekeeper by controlling S phase gene expression mediated by the E2F transcription factor. Consistent with their effect on Rb phosphorylation, PPARg ligands inhibit the mitogenic induction of minichromosome maintenance (MCM) proteins 6 and 7, two E2F-regulated S phase genes essential for DNA replication. PPARg ligands also induced apoptosis in VSMC, which correlated with a potent induction of GADD45, a gene implicated in controlling cell growth and survival. A constitutively active form of PPARg targeted the same cell cycle regulators as did PPARg ligands, consistent with a nuclear-receptor-dependent mechanism of action. This review will summarize mechanisms through which PPARg modulates VSMC proliferation and apoptosis suggesting that PPARg itself is a novel important regulator of cell cycle and apoptosis and may provide a new therapeutic approach to prevent restenosis.
Peroxisome proliferator-activated receptor {gamma} (PPARg) ligands have been shown to inhibit growth of vascular and cancer cells by interfering with the expression and function of multiple cell cycle regulators. [1] [2] [3] [4] [5] [6] Although many studies have focused on alterations in the regulation of cell growth as a fundamental feature during atherogenesis and neointimal hyperplasia after percutaneous coronary revascularization, it is becoming increasingly evident that perturbations in the regulation of cell death may be of equal importance. 7 In vascular smooth muscle cells (VSMC), we have previously reported that the thiazolidinedione (TZD) PPARg ligands, troglitazone (TRO) and rosiglitazone (RSG), inhibit exit from G1 into S phase of the cell cycle by attenuating retinoblastoma protein (Rb) phosphorylation. 4 As illustrated in Figure 1 decreased phosphorylation of Rb by TRO and RSG likely results from their effect to elevate levels of the cyclindependent kinase inhibitor (CDKI) p27 kip1 and reduce the activity of cyclin D-and cyclin E-dependent kinases (CDK). 4 In addition, recent studies have shown that TZDs not only inhibit cell growth, but they can also induce apoptosis in VSMC. 8, 9 The molecular mechanisms by which TZDs induce apoptosis in VSMC and whether they involve a PPARgdependent pathway also remain unclear.
Using DNA microarray analysis, we have identified additional target genes mediating the antiproliferative and proapoptotic effects of PPARg ligands. 10, 11 A biased DNA array containing 96 genes known to control the cell cycle was used to screen for nuclear targets that potentially mediate the antiproliferative activity of PPARg ligands on VSMC. Using this approach, we found that PPARg inhibited expression of genes encoding the minichromosome maintenance proteins (MCM) 6 and 7. 12 MCM proteins play a central role in the regulation of the initiation of DNA replication and ensure that DNA replicates only once during each cell cycle (reviewed by Tye 13 ). In eukaryotes, MCM2-MCM7 are recruited onto replication origins during the G1 phase of the cell cycle and assembled into a heteromeric hexamer. Formation of this prereplication complex, a process often referred to as 'replication licensing', establishes the competence of this origin for initiation of DNA replication in the subsequent S phase. The promoter regions of MCM6 and MCM7 contain several elements for E2F indicating that this transcription factor may be primarily responsible for the coordinated increase in MCM mRNA during the G1-S phase transition. 14, 15 Entry into S phase requires increased phosphorylation of the Rb, which releases sequestered E2F to permit transcription of genes encoding the replicative machinery for DNA synthesis, including MCM proteins. 16 Phosphorylation of Rb results in a conformational change that releases the entrapped S phase transcription factor, E2F, enabling it to transactivate target genes encoding the enzymatic machinery for DNA synthesis. 16 The MCM6 and MCM7 promoters contain functional E2F binding sites, suggesting that E2F is responsible for the coordinate expression of MCMs during progression through the cell cycle. 14, 15 Consistent with a central role for E2F in regulating MCM expression, we have found that PPARg ligands inhibited E2F-dependent transactivation.
The precise details of how PPARg ligands block G1-S progression and inhibit DNA synthesis are not fully elucidated. Recent findings in PPARg null stem cells have suggested that PPARg ligands may have receptor-independent antiproliferative activities. 6 We observed that inhibition of MCM6 and MCM7 expression by PPARg ligands occurred at concentrations B2 logs higher than its EC 50 for PPARg activation. Despite this right shifting of the doseresponse for PPARg ligand-mediated effects on VSMC, our findings strongly favor a PPARg-dependent mechanism of action. Both a small molecule antagonist, GW9662, and overexpression of dominant-negative PPARg were effective in blocking ligand-mediated repression of MCM7 transcription. In NIH3T3 fibroblasts, which do not express detectable levels of PPARg, 17 PPARg ligands also had no effect on MCM expression. Thus, in these experimental systems corresponding to a loss of PPARg function, PPARg ligands failed to repress MCM7 transcription. Additional evidence that MCMs are bona fide targets for PPARg is provided by experiments using an adenovirus to overexpress a constitutively active form of PPARg in VSMC. Engraftment of the VP16 transactivation domain from herpes simplex virus renders the transcriptional activity of this engineered species of PPARg independent of exogenous synthetic ligands and endogenous natural ligands. We observed that adenoviral overexpression of constitutively active PPARg potently inhibited the mitogen-induced expression of MCM7 mRNA and protein, similar to effects observed with the PPARg ligands. Inhibition of MCM expression by the constitutively active PPARg is unlikely to be attributed to a nonspecific effect of the VP16 transactivation domain because MCM7 transcription was suppressed by the constitutively-active PPARg but not by the overexpression of the VP16 transactivation domain alone. In concert, these observations support the conclusion that the inhibitory effect of constitutively active PPARg and PPARg ligands on MCM expression is mediated through a PPARg-dependent mechanism.
DNA microarray analysis also identified the growth arrest and DNA damage-inducible (GADD) gene GADD45 as a gene prominently upregulated by PPARg ligands.
11 GADD45 is a member of a group of genes induced by agents that damage Kip1 degradation through ubiquitination and proteolysis by PPARg reduces the activity of cyclin D-and cyclin E-dependent kinases (CDK). Decreased CDK activity prevents phosphorylation of Rb resulting in decreased E2F release and reduced transcription of E2F-target genes, such as MCMs, finally leading to an inhibition of DNA synthesis.
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DNA and/or cause growth arrest. 18 Increased GADD45 gene expression has been detected in many mammalian cell types and has been implicated in growth suppression 19 and apoptosis. 20, 21 Although the exact function of GADD45 remains unclear, evidence has emerged that GADD45 is a cell cycle regulated nuclear protein that reaches maximal levels in the G1 phase of the cycle. 22 Through its association with Cdc2, GADD45 disrupts the interactions of Cdc2 with cyclin B1 and, thus, may induce G2/M arrest. 23 The GADD genes, therefore, may represent a unique target for drugs that induce cell cycle arrest, apoptosis and differentiation such as PPARg ligands (Figure 2 ). GADD45 is prominently induced in growth-arrested cells 19 and in those undergoing apoptosis. 20, 21 Induction of apoptosis through GADD45-dependent pathways involves activation of JNK and p38 MAPK pathways. 20, 21 Since PPARg activation inhibits cell proliferation and/or triggers apoptosis in a wide variety of mammalian cells, we hypothesized that upregulation of GADD45 by PPARg ligands may be involved in their proapoptotic and antiproliferative activities. Baseline levels of GADD45 mRNA in growing human coronary VSMC were low, but increased substantially after treatment with PPARg ligands reaching maximal levels after 48 h. These findings indicated that ligand-dependent activation of PPARg can lead to growth arrest and induction of apoptosis in VSMC, at least in part, by inducing GADD45 mRNA expression.
To determine whether activation of PPARg induces apoptosis and GADD45 expression, we again employed adenoviral-mediated overexpression of constitutively active form of PPARg. Infection of VSMC with Adx-CA-PPARg resulted in marked dose-dependent overexpression of constitutively active PPARg protein, which induced apoptosis as evidenced by increased annexin V binding as well as an upregulation of GADD45 mRNA levels. These findings demonstrate that ligand-independent activation of PPARg specifically induces caspase-mediated apoptosis of VSMC and GADD45 mRNA expression and provides evidence that the induction of GADD45 by PPARg ligands is mediated through a PPARgdependent mechanism. The PPARg-mediated induction of GADD45 mRNA could result from either an effect to increase transcription and/or promote enhanced mRNA stability. GADD45 mRNA levels have been shown to be regulated by both transcriptional activation and post-transcriptional mRNA stabilization depending on the cell type and specific inducer. Since the half-life of GADD45 mRNA in control and PPARg ligand-treated cells was nearly identical, PPARg ligands did not enhance the GADD45 mRNA stability in VSMC.
To examine the effect of PPARg ligands on GADD45 transcription, VSMC were transiently transfected with a human GADD45 promoter construct containing 2543 bp of 5 0 -flanking DNA for the GADD45 gene inserted upstream of a luciferase reporter (pG45-Luc). 24 PPARg ligands induced GADD45 promoter activity by 2-3-fold. To identify the PPARg-responsive elements in the GADD45 promoter, a deletion series of luciferase reporter constructs spanning the different regions of the human GADD45 promoter was employed. Progressive 5 0 -deletions of the promoter that extended to À81 relative to the transcription start site exhibited almost no induction following treatment with PPARg ligands. The region between À234 and À81, therefore, contains critical elements required for activation of the High-level expression of functional PPARg in intimal VSMC, therefore, provides an attractive therapeutic target to exploit the antiproliferative and proapoptotic properties of PPARg ligands. Inhibition of MCM expression and upregulation of GADD45 levels by PPARg may play a prominent role in limiting neointimal hyperplasia after mechanical injury to the arterial wall. Early clinical trials with TRO and pioglitazone have demonstrated an almost 50% reduction in neointimal tissue formation after coronary stent-implantation to treat diabetes-associated macrovascular disease. [31] [32] [33] Further identification of novel PPARg ligands based on their direct vascular activity, as opposed to their portfolio of metabolic effects on glucose and lipids, may yield compounds with even greater efficacy against proliferative vascular diseases.
